Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, Australia.
Wong P, Whiteman DC, Olsen CM, Yuan Y, Butler J, Curley C, Durrant S, Henden A, Morton J, Subramoniapillai E, Stewart C, Tey SK, Kennedy GA, Scott AP. Wong P, et al. Among authors: subramoniapillai e. Bone Marrow Transplant. 2024 Jan;59(1):144-146. doi: 10.1038/s41409-023-02138-6. Epub 2023 Oct 27. Bone Marrow Transplant. 2024. PMID: 37891378 No abstract available.
High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantation.
Yuan Y, Wong P, Butler JP, Henden A, Curley C, Durrant S, Mediwake H, Morton AJ, Stewart C, Subramoniapillai E, Weber N, Tey SK, Kennedy GA, Scott AP. Yuan Y, et al. Among authors: subramoniapillai e. Bone Marrow Transplant. 2022 Nov;57(11):1712-1715. doi: 10.1038/s41409-022-01773-9. Epub 2022 Aug 15. Bone Marrow Transplant. 2022. PMID: 35970876 No abstract available.
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance.
Boyle S, Tobin JWD, Perram J, Hamad N, Gullapalli V, Barraclough A, Singaraveloo L, Han MH, Blennerhassett R, Nelson N, Johnston AM, Talaulikar D, Karpe K, Bhattacharyya A, Cheah CY, Subramoniapillai E, Bokhari W, Lee C, Hawkes EA, Jabbour A, Strasser SI, Chadban SJ, Brown C, Mollee P, Hapgood G. Boyle S, et al. Among authors: subramoniapillai e. Hemasphere. 2021 Oct 11;5(11):e648. doi: 10.1097/HS9.0000000000000648. eCollection 2021 Nov. Hemasphere. 2021. PMID: 34651103 Free PMC article.
A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.
Kennedy GA, Tey SK, Buizen L, Varelias A, Gartlan KH, Curley C, Olver SD, Chang K, Butler JP, Misra A, Subramoniapillai E, Morton AJ, Durrant S, Henden AS, Moore J, Ritchie D, Gottlieb D, Cooney J, Paul SK, Hill GR. Kennedy GA, et al. Among authors: subramoniapillai e. Blood. 2021 Apr 8;137(14):1970-1979. doi: 10.1182/blood.2020009050. Blood. 2021. PMID: 33512442 Free article. Clinical Trial.
Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation.
Henden AS, Varelias A, Leach J, Sturgeon E, Avery J, Kelly J, Olver S, Samson L, Hartel G, Durrant S, Butler J, Morton AJ, Misra A, Tey SK, Subramoniapillai E, Curley C, Kennedy G, Hill GR. Henden AS, et al. Among authors: subramoniapillai e. Blood Adv. 2019 Oct 22;3(20):3013-3019. doi: 10.1182/bloodadvances.2019000453. Blood Adv. 2019. PMID: 31648324 Free PMC article. Clinical Trial.
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Kennedy GA, Varelias A, Vuckovic S, Le Texier L, Gartlan KH, Zhang P, Thomas G, Anderson L, Boyle G, Cloonan N, Leach J, Sturgeon E, Avery J, Olver SD, Lor M, Misra AK, Hutchins C, Morton AJ, Durrant ST, Subramoniapillai E, Butler JP, Curley CI, MacDonald KPA, Tey SK, Hill GR. Kennedy GA, et al. Among authors: subramoniapillai e. Lancet Oncol. 2014 Dec;15(13):1451-1459. doi: 10.1016/S1470-2045(14)71017-4. Epub 2014 Nov 14. Lancet Oncol. 2014. PMID: 25456364 Clinical Trial.